Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 6;8(11):1745.
doi: 10.3390/microorganisms8111745.

New Technologies for Influenza Vaccines

Steven Rockman  1   2 , Karen L Laurie  1 , Simone Parkes  1 , Adam Wheatley  2 , Ian G Barr  2   3
Affiliations
Review

New Technologies for Influenza Vaccines

Steven Rockman et al. Microorganisms. .

Abstract

Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.

Keywords: cell-based influenza vaccines; cell-culture; egg-based influenza vaccines; influenza; mRNA vaccines; recombinant vaccines; universal vaccine; vaccine.

PubMed Disclaimer

Conflict of interest statement

S.R., K.L.L., S.P. and I.G.B. have shares in an influenza vaccine producing company. S.R., K.L.L. and S.P. are employed by Seqirus. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza (IB) has received financial support for research activities from influenza vaccine producing companies. AW declares no conflict of interest.

Figures

Figure 1
Figure 1
Potential steps and technologies to improve influenza vaccines. Stepwise improvements that might lead to the eventual generation of an effective universal influenza vaccine. Achieved (green), partially achieved (yellow) and in-development/not achieved (red). Listed beside the steps as dot points are strategies that might be used to achieve these outcomes, with question marks indicating strategies that are still in development or have not achieved this outcome to date.
See this image and copyright information in PMC

References

    1. Molinari N.-A.M., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., Bridges C.B. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine. 2007;25:5086–5096. doi: 10.1016/j.vaccine.2007.03.046. - DOI - PubMed
    1. Influenza (Seasonal) [(accessed on 20 July 2020)]; Available online: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
    1. Influenza (Flu) Who is at High Risk for Flu Complications. [(accessed on 24 August 2020)]; Available online: https://www.cdc.gov/flu/highrisk/index.htm.
    1. Influenza (Flu) Past Pandemics. [(accessed on 24 August 2020)]; Available online: https://www.cdc.gov/flu/pandemic-resources/basics/past-pandemics.html.
    1. Sutton T.C. The Pandemic Threat of Emerging H5 and H7 Avian Influenza Viruses. Viruses. 2018;10:461. doi: 10.3390/v10090461. - DOI - PMC - PubMed

LinkOut - more resources